<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2164</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"/><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>THE NEED OF PHARMACOVIGILANCE OF DISULFIRAM - A REVIEW&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mane</surname><given-names>Prafulla</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thosar</surname><given-names>Ambrish</given-names></name></contrib><contrib contrib-type="author"><name><surname>Atre</surname><given-names>Kavita</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mayee</surname><given-names>Rahul</given-names></name></contrib></contrib-group><volume/><issue/><fpage>92</fpage><lpage>97</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>A good pharmacovigilance practice is the need of time to ensure that the drugs in the market are fulfilling the purpose for what they are meant. Similarly, the literature survey highlights the miracle drug i.e. disulfiram which is showing promising results and giving a sigh of relief to the families from the rural areas of our country by enabling the alcohol dependent patients to quit alcohol. . Disulfiram is a drug used to support the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram is also being studied as a treatment for cocaine dependence, as it prevents the breakdown of dopamine. Several studies have reported that it has anti-protozoal activity as well. There is no tolerance to disulfiram: the longer it is taken, the stronger its effects. The adverse drug reactions (ADRs) of disulfiram are themselves used as a treatment for alcoholism. So, the more we get pharmacovigilant about the drug the more it will be fruitful for us to treat the patient. Hence, we can call disulfiram as one of the life saving drugs for the alcohol addicts knowing the consequences of excessive consumption of alcohol.&#13;
</p></abstract><kwd-group><kwd>Pharmacovigilance</kwd><kwd> disulfiram</kwd><kwd> alcoholism</kwd><kwd> adverse drug reaction.</kwd></kwd-group></article-meta></front></article>
